Showing session: reset
Novel Immuno-oncology Strategies
- Sort by:
- Browse by:
- Free
- slides video
- audio + slides
- All slides included
Intratumoral toll-like receptor 9 (TLR9) agonist, CMP-001, in combination with pembrolizumab can reverse resistance to PD-1 inhibition in a phase Ib trial in subjects with advanced melanoma
Mohammed Milhem
University of Iowa, Iowa City, IA, United States
- Free
- slides video
- audio + slides
- All slides included
Discussant
Jedd Wolchok
Mem. Sloan Kettering Cancer Ctr., New York, NY, United States
- Permission not
granted for presentation
A Cancer Research UK phase I trial of anti-GD2 chimeric antigen receptor (CAR) transduced T-cells (1RG-CART) in patients with relapsed or refractory neuroblastoma
Karin Straathof
UCL Great Ormond Street Institute of Child Health, London, United Kingdom
- Free
- slides video
- audio + slides
- All slides included
First-in-human phase I combination of the IL-15 receptor super agonist complex ALT-803 with a therapeutic (anti-CD20) monoclonal antibody (mAb) for patients with relapsed or refractory indolent non-Hodgkin lymphoma (iNHL)
Todd A Fehniger
Washington University School of Medicine, Saint Louis, MO, United States
- Free
- slides video
- audio + slides
- All slides included
Discussant
Thomas A. Waldmann
National Cancer Inst., Bethesda, MD, United States
- Free
- slides video
- audio + slides
- All slides included
Safety and efficacy of high purity and activity NK cells therapy in combination with IgG1 antibody in patients with gastric or colorectal cancer: A phase I clinical trial
Naoyuki Sakamoto
Kyoto Prefectural University of Medicine, Kyoto, Japan
- Free
- slides video
- audio + slides
- All slides included
Discussant
William Carson
Ohio State Univ., Columbus, OH, United States